Analisi costo/efficacia della doxofillina vs. teofillina nella terapia dell’asma cronica reversibile dell’adulto by Mario Eandi, Elisa Berno, Lorenzo Pradelli

“…Clinical trials prooved that while doxofylline is as effective as theophylline in the treatment of asthma, it is associated with lesser side effects. For our pharmacoeconomical evaluation, we employed the data of an international multi-centric study that compared the efficacy and tolerability of 12 weeks of treatment with either theophylline 250 mg tid, or doxofylline 400 mg tid, or placebo. …”
Get full text

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis by Jerry Bagel, Elise Nelson, James Zapata, Alexa Hetzel

“…The improved efficacy was maintained throughout the additional 12 weeks of maintenance Cal/BD foam application. The pharmacoeconomic evaluation demonstrated that adjuvant use of Cal/BD foam led to cost savings compared with switching biologic treatments. …”
Get full text

Understanding the decision making process of selection of medicines in the private sector in South Africa – lessons for low-middle income countries by Velisha Ann Perumal-Pillay, Fatima Suleman

“…Most schemes expressed a difficulty with lack of information to support pharmacoeconomic evaluations of medicines for inclusion on the formulary. …”
Get full text

Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS) by Georgios Tsivgoulis, Spyros Deftereos, Claudio Gobbi, Elisabeth Gulowsen Celius, Alina Kulakowska, Giorgia Maniscalco, Irene Mendes, Nicolaos Grigoriadis

“…Conclusions CLAD CROSS will provide efficacy data on cladribine tablets, used as a follow-up treatment to first-line DMDs in the real-world setting, will further establish its safety profile and will collect information to support pharmacoeconomic studies.…”
Get full text

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients by Zhang C, Ke WX, Liu L, Gao YH, Yao ZJ, Ye XH, Zhou SD, Yang Y

“…Chi Zhang,* Weixia Ke,* Li Liu, Yanhui Gao, Zhenjiang Yao, Xiaohua Ye, Shudong Zhou, Yi Yang Department of Epidemiology and Biostatistics, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong, People’s Republic of China *These authors contributed equally to this work Background/aim: Lamivudine (LAM) plus adefovir (ADV) combination therapy is clinically efficacious for treating chronic hepatitis B (CHB) patients in China, but no pharmacoeconomic evaluations of this strategy are available. …”
Get full text

Multi-aspect approach to the optimization of pharmacotherapy of patients with arterial hypertension of high and very high risk by Svetlana Gridina

“…Evaluation of the efficacy, safety and individualization of a therapy was carried out by using pharmacokinetic, pharmacoeconomic, sonographic, and laboratory methods. …”
Get full text

The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists by S. K. Zyryanov, I. N. Dyakov

“…Sensitivity analysis has been provided for validation of results. Results. Pharmacoeconomic analysis for all drugs included into analysis has shown of economic advantages of effective DM2T control. iGlaLixi has demonstrated economic advantages as well usage aGLP-1 only (direct costs decreasing vs Exe on 37,8 %, vs Dula on 31,8 %, vs Lira on 63,5 %, vs Sema - on 41,9 %) as vs iDegLira - on 36,1 %. iGlaLixi decreased a total cost (direct and non-direct) better than Exe, Dula, Lira and Sema (on 30,7; 22,3; 52,1 and 30,4 % accordingly. …”
Get full text

Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis by Vena GA, Cassano N, Iannone F

“…A brief mention of pharmacokinetics, pharmacodynamic features and pharmacoeconomic considerations is also given. Keywords: subcutaneous methotrexate, efficacy, tolerability, juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic disease…”
Get full text

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE... by Young G, Solem CT, Hoffman K, Kabawat J, Pickard AS, Gut RZ, Cooper DL

“…Guy Young,1 Caitlyn T Solem,2,3 Kate Hoffman,4 Jenna Kabawat,4 A Simon Pickard,3 Robert Z Gut,5 David L Cooper51Children's Center for Cancer and Blood Disorders, Children's Hospital Los Angeles, Los Angeles, CA, 2Pharmerit, Bethesda, MD, 3Center for Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, 4Outcome Sciences, Cambridge, MA, 5Novo Nordisk Inc, Princeton, NJ, USAObjective: The daily recordings of treatment by patients with congenital hemophilia with inhibitors and their caregivers were assessed as part of the Dosing Observational Study in Hemophilia (DOSE) to understand the patterns of bypassing agent use and health-related quality of life.Methods: Frequently bleeding patients prescribed recombinant activated factor VII as first-line therapy were eligible. …”
Get full text

Considerazioni cliniche ed economiche nel trattamento del cancro della prostata: analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH by Monia Marchetti, Giorgio Lorenzo Colombo

“…When conducing the cost/effectiveness analysis, the survival advantage associated to bicalutamide has been adjusted to balance the low quality of life of PC patients. The pharmacoeconomical benefit of bicalutamide resulted of 12,150 Euro/QALY, while the cost per year of life saved resulted inferior, ranging from 8.327 to 11.440 Euro. …”
Get full text

COMPARATIVE EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION ACCOMPANIED BY TYPE 2 DIABETES by E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk

“…Conclusion. According to pharmacoeconomic analysis the fixed combination of original enalapril+hydrochlorothiazide and the fixed combination of original perindopril+indapamide should be used in patients with moderate arterial hypertension, endothelial dysfunction and/or MAU.…”
Get full text

Comparative efficacy, safety, and cost of iron chelation monotherapy vs. combination therapy in pediatric beta-thalassemia major: a single-center retrospective study by Dewi Sharon Simorangkir, Nafrialdi Nafrialdi, Pustika Amalia Wahidiyat, Vivian Soetikno

“…Safety was analyzed descriptively. A pharmacoeconomic analysis was performed based on clinical outcomes consisting of effectiveness and direct medical costs. …”
Get full text

The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. by van Staa, T, Kanis, J, Geusens, P, Boonen, A, Leufkens, H, Cooper, C

“…Including bone mineral density in the risk assessment, the cost per QALY gained was 35k pounds in women at age 60 with a fracture history and a T-score of -2.5 (at age 80, this was 3k pounds). CONCLUSION: A pharmacoeconomic model based on individual long-term risks of fracture improves the selection of postmenopausal women for cost-effective treatment with bisphosphonates.…”

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Mod... by Zhuang Cui, Wei Zhou, Qinxue Chang, Tiantian Zhang, Hui Wang, Xiangda Meng, Yuanyuan Liu, Hua Yan

“…As effective drugs of the treatment, conbercept and ranibizumab have been commonly used and covered by the national basic medical insurance in China. However, the pharmacoeconomic evaluation of conbercept vs. ranibizumab for DME and PM remains lacking. …”
Get full text

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach by Wen Hui, Ruomeng Song, Hongyu Tao, Zhixiang Gao, Min Zhu, Mingyue Zhang, Huazhang Wu, Daichen Gong, Xiyan Zhang, Yuanyi Cai

“…However, there is paucity of evidence on direct pharmacoeconomic studies related to immunotherapy combinations. …”
Get full text

OPTIMIZATION OF PHARMACEUTICAL CARE FOR JUVENILE RHEUMATOID ARTHRITIS AT THE REGIONAL LEVEL by A. A. Skripko, L. N. Geller, G. G. Radnaev, Т. V. Hadanova

“…Clinical practice and content analysis of scientifi c literature indicate that for treatment of the immune-infl amatory disease called juvenile rheumatoid arthritis (JRA), the use of only basic medicines (BM) is not suffi cient.The aim of the study is the organization of pharmacotherapy of JRA patients by genetically engineered biological preparations (GEBP), affecting the immune processes of the body directly.Materials and methods: the theory of marketing, content analysis, the ABC-analysis, sociological survey, pharmacoeconomic methods.Results and discussion. Depending on the individual characteristics of patients, the clinical picture of the disease can manifest itself in different ways, which requires justifi cation of the necessary schemes of GEBP pharmacotherapy at each stage of the carried out treatment. …”
Get full text

Respiratory-Kinesiological Rehabilitation in the Early Periods after Cardiosurgical Interventions by G. P. Plotnikov, Ye. V. Malakhov, B. L. Hayes, Ye. V. Grigoryev, L. S. Barbarash

“…The positive result from a primary pharmacoeconomic analysis for surviving patients is shown. …”
Get full text

GOLD severity stratification and risk of hospitalisation for COPD exacerbations by M. Lusuardi, C. Lucioni, F. De Benedetto, S. Mazzi, C.M. Sanguinetti, C.F. Donner

“…The Italian Costs for Exacerbations in COPD (“ICE”) study, following a pharmacoeconomic assessment of costs due to COPD exacerbations (primary endpoint), aimed also at evaluating (secondary endpoint) which clinical factors, among those considered for cost-analysis, may, at follow up, present a risk of new exacerbations and re-admission to hospital. …”
Get full text

The role and place of the pharmacist-cosmetologist in the choosing and implementation of a cosmetology procedure for hair removal by N. O. Tkachenko, T. V. Mahanova, H. I. Makurina, N. V. Hrinivetska

“…The specialist can offer the client (patient) the choice of a method and directly carry out the procedure, having knowledge and experience in diagnosing the condition of the skin and its appendages and understanding the specifics of CPHR against the background of the pharmacoeconomic analysis. The modern Ukrainian model of pharmacist-cosmetologist training allows marketing requirements and accompanying the customer at CPHR. …”
Get full text

An observational study to assess the outcomes of treatment of patients with stable angina after planned percutaneous coronary intervention: baseline patient characteristics by L. G. Ratova, E. N. Parizhskaya, K. A. Kovaleva, A. O. Nedoshivin, O. D. Nemyatykh, V. V. Pulit, A. O. Konradi

“…Patients with stable CAD who underwent PCI are a representative sample which allows the assessment of treatment outcomes, an objective assessment of the intervention and the calculation of pharmacoeconomic parameters. An observational study will help identifying the factors affecting the efficiency of surgery and getting knowledge of patients’ opinions about this method.…”
Get full text